

Corporate Presentation

(NASDAQ: TTOO)

April 2024

Forward-Looking Statements

This presentation contains forward-looking statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. ("we", "us", "our", "T2", "T2 Biosystems" or the "Company") and include those about T2's goals, strategies, plans, objectives, prospects, milestones, future operations, business and industry, anticipated product benefits, future events and conditions and potential scenarios. Such statements and those that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the federal securities laws or otherwise. Forward-looking statements address matters that involve risks and uncertainties. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, for example: (i) our status as an early commercial-stage company and expectation to incur losses in the future; (ii) our ability to obtain marketing authorization from the FDA or regulatory clearance for additional product candidates in the United States or abroad; (iii) the market acceptance of our technology; (iv) our ability to timely and successfully develop and commercialize existing and future product candidates; (v) our lengthy and variable sales cycle and lack of sales history; (vi) our ability to successfully manage growth; (vii) federal, state and foreign regulatory requirements; (viii) our uncertain future capital needs and ability to raise future capital; (ix) dependence on third parties; (x) recruiting, training and retaining key personnel; (xi) competitive factors; (xii) manufacturing and other product risks; (xii) risks related to intellectual property; and (xiii) other risk factors included in our annual report on form 10-K filed with the Securities and Exchange Commission (SEC) on April 1, 2024 and other documents we file with the SEC from time to time. Accordingly, there are or will be important factors that could cause our actual results to differ materially from those indicated in these statements. The statements made herein speak only as of the date of this presentation. We do not undertake, and specifically disclaim, any obligation to update any forward-looking statements contained in this presentation.

Board of Directors



John Sperzel

Chairman, President & CEO
T2 Biosystems, Inc.



Seymour Liebman

Executive VP & General Counsel
Canon, Inc.



Laura Adams

Special Advisor
National Academy of Medicine



Ninfa Saunders Ph.D

Former President & CEO
Navicent Health (GA)



Jack Cumming

Former Chairman & CEO
Hologic, Inc.



Robin Toft

Former Sr. Vice President
Roche Molecular Diagnostics



David Elsbree

Former Sr. Partner
Deloitte & Touche

Investment Highlights

Proprietary technology platform with potential to become standard of care in sepsis management

Proprietary Platform



Innovative proprietary technology platform (magnetic resonance)

Novel Sepsis Diagnostics



Direct from blood ID in 3-5 hours (culture independent)

Large Market Opportunity



Initial target market \$2 billion+

Established Reimbursement



U.S. hospital in-patient testing is covered (DRG payment system)

Robust Product Pipeline



BARDA contract provided \$31 million to advance pipeline

Commercially Focused



Commercial focus on global hospital market



Our mission is to fundamentally change the way medicine is practiced through **transformative culture-independent diagnostics** that improve the lives of patients around the world

Sepsis is a Global Problem with Fatal Consequences

An estimated 11 million people worldwide die from sepsis each year



Sepsis contributes to
1 in 5 deaths
globally

Significant Human and Economic Toll from Sepsis in the U.S.

Causes more deaths each year than the top three cancers combined (i.e., lung, colorectal, breast)²



Sepsis is the #1 cost
of U.S. hospitalization:
\$62 billion annually¹




Sepsis is the #1 cause
of death in U.S. hospitals:
270,000 annually³




Sepsis is the #1 cause
of 30-day readmission:
19% readmission⁴

The Challenge of Detecting Sepsis-Causing Pathogens

It is a race against time, as each hour of delayed treatment increases mortality by up to 8%



Rapid Detection of Sepsis-Causing Pathogens is Critical



T2 Biosystems' products are able to detect sepsis-causing pathogens and antibiotic resistance genes directly from whole blood within 3-5 hours, without the need to wait days for positive blood culture, enabling clinicians to achieve faster targeted antimicrobial

The Only FDA-Cleared Direct-From-Blood Sepsis Tests

Fully-automated T2Dx Instrument and Sepsis Tests are Rapid, Easy-to-Use and Reliable

- Rapid: results in 3-5 hours
- Simple: no sample preparation
- Ultra Sensitive: 1 CFU/mL
- T2MR technology is not inhibited by prior antimicrobial administration³



T2Candida®	T2Bacteria®	T2Resistance™
Sensitivity: 91.1% ¹ Specificity: 99.4% ¹	Sensitivity: 95.4% ² Specificity: 98.0% ²	FDA Breakthrough Device CE Mark/RUO 2019
<i>C. albicans</i> <i>C. tropicalis</i> <i>C. parapsilosis</i> <i>C. krusei</i> <i>C. glabrata</i>	<i>E. faecium</i> <i>S. aureus</i> <i>K. pneumoniae</i> <i>A. baumannii</i> <i>P. aeruginosa</i> <i>E. coli</i>	<i>mecA/C</i> <i>vanA/B</i> CTXM-14/15 KPC OXA-48 Group NDM, VIM, IMP AmpC (CMY/DHA)
FDA-Cleared CE-marked 1-3 CFU/mL LoD	FDA-Cleared CE-marked 2-11 CFU/mL LoD	U.S. clinical trial (patient enrollment complete) CE-marked 3-11 CFU/mL LoD

1. Mylonakis, E., Clancy, C.J., Ostrosky-Zeichner, L., et al. (2015). Clinical Infectious Diseases
2. T2Bacteria Pivotal Clinical Study. This is a combination of samples run in both prospective and contrived arms of study. T2Bacteria showed an overall average sensitivity of 90% in the prospective arm of the study and the contrived arm an overall average PPA of 97%.
3. T2Candida and T2Bacteria Instructions for Use, refer to Performance Characteristics: Interfering Substances

The FDA-Cleared Multi-Target T2Biothreat Panel

Unique targets with unparalleled sensitivity and specificity

- The T2Biothreat Panel is an FDA-cleared qualitative, multiplexed, nucleic acid-based in vitro diagnostic test that runs on the T2Dx[®] Instrument
- Infections with the six pathogens on the T2Biothreat Panel can result in mortality rates of 40-90%
- Detects six bioterrorism-related species recognized by the PHEMCE High Priority Biological Threats List posted by ASPR¹
- The only multi-target biothreat panel developed and manufactured by U.S. corporation
- Developed under multi-year product development contract with the U.S. Government (BARDA)
- Sensitivity of 100% for all targets except *F. tularensis* (94.3%), and specificity of 100% for all six targets



Species	Disease
<i>Bacillus anthracis</i>	Anthrax
<i>Burkholderia mallei</i>	Glanders
<i>Burkholderia pseudomallei</i>	Melioidosis
<i>Francisella tularensis</i>	Tularemia (rabbit fever)
<i>Rickettsia prowazekii</i>	Epidemic typhus
<i>Yersinia pestis</i>	Plague

Growing Independent Support for T2 Biosystems' Products



T2Bacteria® Panel and T2Candida® Panel are included in **dozens of independent, real-world clinical case studies** demonstrating clinical utility (www.t2biosystems.com)



FDA **granted Breakthrough Device designation for three pipeline products**, including T2Resistance Panel, the T2Lyme™ Panel and the *Candida auris* test



CMS **established T2Bacteria Panel as first diagnostic product to gain incremental reimbursement via New Technology Add-on Payment (NTAP)**¹



Vizient, Inc. **awarded T2 Biosystems with Innovative Technology contract**, providing access to 50% of the nation's acute care hospitals and 95% of academic medical centers



BARDA **provided T2 Biosystems \$31 million in product development funding** (from 2019-2023) to advance the T2Biothreat Panel, T2Resistance Panel, and next-generation sepsis products



U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation **named T2 Biosystems a winner in LymeX Diagnostics Prize** with potential for a portion of up to \$9 million in future funding

Meta-analysis of 14 Controlled Studies (Peer-Reviewed)

Highlights benefits of T2 Biosystems sepsis technology vs. blood culture

Title: Antimicrobial and Resource Utilization with T2 Magnetic Resonance for Rapid Diagnosis of Bloodstream Infections: Systematic Review with Meta-analysis of Controlled Studies (2021)

Authors: Maddalena Giannella, George A. Pankey, Renato Pascale, Valerie M. Miller, Larry E. Miller, Tamara Seitz

Journal: Expert Review of Medical Devices

Seven Outcomes Evaluated

- Time to **detection 81 hours faster** with T2MR
- Time to **species identification 77 hours faster** with T2MR
- Patients testing positive on T2MR **received targeted antimicrobial therapy 42 hours faster**
- Patients testing negative on T2MR **de-escalated from empirical therapy 7 hours faster**
- Length of **ICU stay 5 days shorter** with T2MR
- Length of **hospital stay 4.8 days shorter** with T2MR
- Mortality rates were comparable between T2MR and BC



2024 Corporate Priorities



ACCELERATE SALES



ENHANCE OPERATIONS



ADVANCE PIPELINE

1

ACCELERATE SALES

Commercial Go-To-Market Strategy

Increase T2Dx Instrument installed base and expand sepsis testing

UNITED STATES MARKET

- Installed base: 94 T2Dx Instruments
- Enhanced customer training program
- Instrument placement programs

INTERNATIONAL MARKETS

- Installed base: 99 T2Dx Instruments
- Pursue geographic expansion
 - EU/ME, APAC, and LATAM
- Enhanced distributor training and support

Commercial Execution

Driving changes to standard of care



Educate

Clinical and economic value proposition



ID Use Cases

Patient Selection Criteria:
Hematology/Oncology, ICU,
Transplant



Implement

Secure approval for go-live and
incorporation into sepsis protocol



Routine

Establish patient sample and
results reporting workflow
Post-Go Live Customer Support



Instrument Installs



Prepared to run clinical samples



Routine clinical use

2

ENHANCE OPERATIONS

Operational Objectives

- Achieve on-time delivery targets
- Reduce inventory
- Reduce scrap
- Reduce operating costs
- Transfer new products from R&D
- Implement Oracle ERP system



3

ADVANCE PIPELINE

T2 Biosystems

New Product Pipeline: Test Menu Expansion Initiatives

Designed to expand the test menu on the FDA-cleared T2Dx Instrument

T2Resistance Panel

- Direct-from-blood test panel designed to detect 13 antibiotic resistance genes, in 3-5 hours, without the need to wait days for blood culture results
- Proposed to confer resistance to common antibiotics, including carbapenems, vancomycin, β -lactams, methacilin
- Received FDA Breakthrough Device designation; completed U.S. trial patient enrollment; plan to file FDA submission for 510(k) in Q3 2024

T2Candida Panel Expansion (add *C. auris*)

- Direct-from-blood test designed to detect *Candida auris*, in 3-5 hours, without the need to wait days for blood culture results
- *C. auris* is a multidrug-resistant fungal pathogen that is recognized as a global health threat by CDC and WHO; mortality rate up to 60%
- Received FDA Breakthrough Device designation; developed *C. auris* test in collaboration with CDC

T2Bacteria Panel Expansion (add *A. baumannii*)

- Direct-from-blood test designed to detect *Acinetobacter baumannii*, in 3-5 hours, without the need to wait days for blood culture results
- *A. baumannii* considered the tenth most common bacterial pathogen with ICU mortality rate of 34%-43%; can be resistant to many antibiotics
- Completed studies to add *A. baumannii* to FDA-cleared T2Bacteria Panel; filed FDA submission in October 2023; **received FDA 510(k) in Feb. 2024**

T2Lyme Panel

- Direct-from-blood test panel designed to detect *Borrelia burgdorferi*, in 3-5 hours, without the need to wait days for blood culture results
- *B. burgdorferi* is the bacteria that causes Lyme disease; T2Lyme Panel is intended to aid in the diagnosis of early Lyme disease
- Received FDA Breakthrough Device designation; received LymeX award, with future funding potential from HHS and Cohen Foundation

Financial Summary

	<u>2024</u>
Total Revenue	\$7.2 million
Product Revenue	\$6.8 million
Instruments	26
Cash Balance	\$15.7 million
(as of December 31, 2023)	

Recent Highlights

- Achieved record sales of T2Bacteria Panel in Q4 2023
- Received FDA 510(k) clearance for T2Biothreat Panel (Sept. 2023)
- Received FDA 510(k) clearance to add *A. baumannii* to the T2Bacteria Panel (Feb. 2024)
- Received FDA Breakthrough Device designation for *Candida auris* test
- Submitted FDA 510(k) premarket notification to expand use of T2Candida Panel to include pediatric testing
- Executed agreement with CRG to convert \$15 million of debt to equity upon receipt of stockholder approval